Modality Solutions to Hold Webinar on Transport Simulation Testing
Validating your cold chain to meet and exceed increasingly stringent regulatory expectations in today’s global...
Case Study: Immunomedics
Immunomedics (www.immunomedics.com) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.
Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of Antibody-Drug Conjugates (ADC).
The US Food and Drug Administration (FDA) has granted fast-track designation for sacituzumab govitecan (IMMUNO-132).
More About This Company
2020 Houston Business Journal Fast 100 List Achieved for Second Year in a Row
Houston-based biopharmaceutical cold chain validation engineering firm Modality Solutions is thrilled to declare it made...
Optimism for DLBCL Patients Across the Globe
Last month, the FDA approved tafasitamab-cxix (official name Monjuvi®) in combination with Lenalidomide as a...
Covid-19 and the Race to Get a Vaccine Through FDA’s Supercharged Fast Track Approval Named Coronavirus Treatment Acceleration Program (CTAP)
The Coronavirus Treatment Acceleration Program launched by the FDA in response to Covid-19 is a...
